References
Afrasyab, A., Qu, P., Zhao, Y., Peng, K., Wang, H., Lou, D., . . . Yuan, D. (2016). Correlation of NLRP3 with severity and prognosis of coronary atherosclerosis in acute coronary syndrome patients. Heart Vessels, 31 (8), 1218-1229. doi:10.1007/s00380-015-0723-8
Ahmed, S., Zimba, O., & Gasparyan, A. Y. (2020). Thrombosis in Coronavirus disease 2019 (COVID-19) through the prism of Virchow’s triad. Clin Rheumatol, 39 (9), 2529-2543. doi:10.1007/s10067-020-05275-1
Albani, F., Sepe, L., Fusina, F., Prezioso, C., Baronio, M., Caminiti, F., . . . Natalini, G. (2020). Thromboprophylaxis with enoxaparin is associated with a lower death rate in patients hospitalized with SARS-CoV-2 infection. A cohort study. EClinicalMedicine, 27 , 100562. doi:10.1016/j.eclinm.2020.100562
Asakura, H., & Ogawa, H. (2021). COVID-19-associated coagulopathy and disseminated intravascular coagulation. Int J Hematol, 113 (1), 45-57. doi:10.1007/s12185-020-03029-y
Bami, S., Vagrecha, A., Soberman, D., Badawi, M., Cannone, D., Lipton, J. M., . . . Levy, C. F. (2020). The use of anakinra in the treatment of secondary hemophagocytic lymphohistiocytosis. Pediatr Blood Cancer, 67 (11), e28581. doi:10.1002/pbc.28581
Bektaş, M., Yüce, S., Ay, M., Uyar, M. H., Önder, M. E., & Kılıç, M. (2023a). High-dose intravenous anakinra treatment is safe and effective in severe and critical COVID-19 patients: a propensity score-matched study in a single center. Inflammopharmacology, 31 (2), 787-797. doi:10.1007/s10787-023-01138-8
Bektaş, M., Yüce, S., Ay, M., Uyar, M. H., Önder, M. E., & Kılıç, M. (2023b). High-dose intravenous anakinra treatment is safe and effective in severe and critical COVID-19 patients: a propensity score-matched study in a single center. Inflammopharmacology , 1-11. doi:10.1007/s10787-023-01138-8
Bettiol, A., Alibaz-Oner, F., Direskeneli, H., Hatemi, G., Saadoun, D., Seyahi, E., . . . Emmi, G. (2023). Vascular Behçet syndrome: from pathogenesis to treatment. Nat Rev Rheumatol, 19 (2), 111-126. doi:10.1038/s41584-022-00880-7
Bilaloglu, S., Aphinyanaphongs, Y., Jones, S., Iturrate, E., Hochman, J., & Berger, J. S. (2020). Thrombosis in Hospitalized Patients With COVID-19 in a New York City Health System. Jama, 324 (8), 799-801. doi:10.1001/jama.2020.13372
Chen, G., Wu, D., Guo, W., Cao, Y., Huang, D., Wang, H., . . . Ning, Q. (2020). Clinical and immunological features of severe and moderate coronavirus disease 2019. J Clin Invest, 130 (5), 2620-2629. doi:10.1172/jci137244
COVID-19 Treatment Guidelines Panel. Coronavirus Disease 2019 (COVID-19) Treatment Guidelines. (2022). National Institutes of Health.Retrieved fromhttps://www.covid19treatmentguidelines.nih.gov/.
Dinarello, C. A. (2011). Interleukin-1 in the pathogenesis and treatment of inflammatory diseases. Blood, 117 (14), 3720-3732. doi:10.1182/blood-2010-07-273417
Everett, B. M., MacFadyen, J. G., Thuren, T., Libby, P., Glynn, R. J., & Ridker, P. M. (2020). Inhibition of Interleukin-1β and Reduction in Atherothrombotic Cardiovascular Events in the CANTOS Trial. J Am Coll Cardiol, 76 (14), 1660-1670. doi:10.1016/j.jacc.2020.08.011
Gabay, C., Lamacchia, C., & Palmer, G. (2010). IL-1 pathways in inflammation and human diseases. Nat Rev Rheumatol, 6 (4), 232-241. doi:10.1038/nrrheum.2010.4
Gabrielli, M., Lamendola, P., Esperide, A., Valletta, F., & Franceschi, F. (2020). COVID-19 and thrombotic complications: Pulmonary thrombosis rather than embolism? Thromb Res, 193 , 98. doi:10.1016/j.thromres.2020.06.014
Giacomelli, R., Sota, J., Ruscitti, P., Campochiaro, C., Colafrancesco, S., Dagna, L., . . . Cantarini, L. (2021). The treatment of adult-onset Still’s disease with anakinra, a recombinant human IL-1 receptor antagonist: a systematic review of literature. Clin Exp Rheumatol, 39 (1), 187-195. doi:10.55563/clinexprheumatol/fsq5vq
Grom, A. A., Horne, A., & De Benedetti, F. (2016). Macrophage activation syndrome in the era of biologic therapy. Nat Rev Rheumatol, 12 (5), 259-268. doi:10.1038/nrrheum.2015.179
Gustine, J. N., & Jones, D. (2021). Immunopathology of Hyperinflammation in COVID-19. Am J Pathol, 191 (1), 4-17. doi:10.1016/j.ajpath.2020.08.009
Horby, P., Lim, W. S., Emberson, J. R., Mafham, M., Bell, J. L., Linsell, L., . . . Landray, M. J. (2021). Dexamethasone in Hospitalized Patients with Covid-19. N Engl J Med, 384 (8), 693-704. doi:10.1056/NEJMoa2021436
Jarczak, D., & Nierhaus, A. (2022). Cytokine Storm-Definition, Causes, and Implications. Int J Mol Sci, 23 (19). doi:10.3390/ijms231911740
Junqueira, C., Crespo, Â., Ranjbar, S., de Lacerda, L. B., Lewandrowski, M., Ingber, J., . . . Lieberman, J. (2022). FcγR-mediated SARS-CoV-2 infection of monocytes activates inflammation. Nature, 606 (7914), 576-584. doi:10.1038/s41586-022-04702-4
Khismatullin, R. R., Ponomareva, A. A., Nagaswami, C., Ivaeva, R. A., Montone, K. T., Weisel, J. W., & Litvinov, R. I. (2021). Pathology of lung-specific thrombosis and inflammation in COVID-19. J Thromb Haemost, 19 (12), 3062-3072. doi:10.1111/jth.15532
Knight, R., Walker, V., Ip, S., Cooper, J. A., Bolton, T., Keene, S., . . . Sterne, J. A. C. (2022). Association of COVID-19 With Major Arterial and Venous Thrombotic Diseases: A Population-Wide Cohort Study of 48 Million Adults in England and Wales. Circulation, 146 (12), 892-906. doi:10.1161/circulationaha.122.060785
Kyriazopoulou, E., Poulakou, G., Milionis, H., Metallidis, S., Adamis, G., Tsiakos, K., . . . Giamarellos-Bourboulis, E. J. (2021). Early treatment of COVID-19 with anakinra guided by soluble urokinase plasminogen receptor plasma levels: a double-blind, randomized controlled phase 3 trial. Nat Med, 27 (10), 1752-1760. doi:10.1038/s41591-021-01499-z
Lachant, D. J., Lachant, N. A., Kouides, P., Rappaport, S., Prasad, P., & White, R. J. (2020). Chronic therapeutic anticoagulation is associated with decreased thrombotic complications in SARS-CoV-2 infection. J Thromb Haemost, 18 (10), 2640-2645. doi:10.1111/jth.15032
Marconi, V. C., Ramanan, A. V., de Bono, S., Kartman, C. E., Krishnan, V., Liao, R., . . . Ely, E. W. (2021). Efficacy and safety of baricitinib for the treatment of hospitalised adults with COVID-19 (COV-BARRIER): a randomised, double-blind, parallel-group, placebo-controlled phase 3 trial. Lancet Respir Med, 9 (12), 1407-1418. doi:10.1016/s2213-2600(21)00331-3
Marko, L., Shemer, A., Lidar, M., Grossman, C., Druyan, A., Livneh, A., & Kivity, S. (2021). Anakinra for colchicine refractory familial Mediterranean fever: a cohort of 44 patients. Rheumatology (Oxford), 60 (6), 2878-2883. doi:10.1093/rheumatology/keaa728
Mehta, P., Cron, R. Q., Hartwell, J., Manson, J. J., & Tattersall, R. S. (2020). Silencing the cytokine storm: the use of intravenous anakinra in haemophagocytic lymphohistiocytosis or macrophage activation syndrome. Lancet Rheumatol, 2 (6), e358-e367. doi:10.1016/s2665-9913(20)30096-5
Middeldorp, S., Coppens, M., van Haaps, T. F., Foppen, M., Vlaar, A. P., Müller, M. C. A., . . . van Es, N. (2020). Incidence of venous thromboembolism in hospitalized patients with COVID-19. J Thromb Haemost, 18 (8), 1995-2002. doi:10.1111/jth.14888
Nigrovic, P. A., Mannion, M., Prince, F. H., Zeft, A., Rabinovich, C. E., van Rossum, M. A., . . . Higgins, G. C. (2011). Anakinra as first-line disease-modifying therapy in systemic juvenile idiopathic arthritis: report of forty-six patients from an international multicenter series. Arthritis Rheum, 63 (2), 545-555. doi:10.1002/art.30128
Phadke, O., Rouster-Stevens, K., Giannopoulos, H., Chandrakasan, S., & Prahalad, S. (2021). Intravenous administration of anakinra in children with macrophage activation syndrome. Pediatr Rheumatol Online J, 19 (1), 98. doi:10.1186/s12969-021-00585-3
Saag, K. G., Khanna, P. P., Keenan, R. T., Ohlman, S., Osterling Koskinen, L., Sparve, E., . . . Terkeltaub, R. (2021). A Randomized, Phase II Study Evaluating the Efficacy and Safety of Anakinra in the Treatment of Gout Flares. Arthritis Rheumatol, 73 (8), 1533-1542. doi:10.1002/art.41699
Sadeghipour, P., Talasaz, A. H., Rashidi, F., Sharif-Kashani, B., Beigmohammadi, M. T., Farrokhpour, M., . . . Bikdeli, B. (2021). Effect of Intermediate-Dose vs Standard-Dose Prophylactic Anticoagulation on Thrombotic Events, Extracorporeal Membrane Oxygenation Treatment, or Mortality Among Patients With COVID-19 Admitted to the Intensive Care Unit: The INSPIRATION Randomized Clinical Trial. Jama, 325 (16), 1620-1630. doi:10.1001/jama.2021.4152
Saunders, B. N., Kuijpers, M. V., Sloan, J. J., & Gertner, E. (2023). Continuous IV infusion of anakinra. Front Pharmacol, 14 , 1162742. doi:10.3389/fphar.2023.1162742
Sefik, E., Qu, R., Junqueira, C., Kaffe, E., Mirza, H., Zhao, J., . . . Flavell, R. A. (2022). Inflammasome activation in infected macrophages drives COVID-19 pathology. Nature, 606 (7914), 585-593. doi:10.1038/s41586-022-04802-1
Stein, L. K., Mayman, N. A., Dhamoon, M. S., & Fifi, J. T. (2021). The emerging association between COVID-19 and acute stroke. Trends Neurosci, 44 (7), 527-537. doi:10.1016/j.tins.2021.03.005
Strati, P., Ahmed, S., Kebriaei, P., Nastoupil, L. J., Claussen, C. M., Watson, G., . . . Westin, J. R. (2020). Clinical efficacy of anakinra to mitigate CAR T-cell therapy-associated toxicity in large B-cell lymphoma. Blood Adv, 4 (13), 3123-3127. doi:10.1182/bloodadvances.2020002328
Tang, N., Bai, H., Chen, X., Gong, J., Li, D., & Sun, Z. (2020). Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy. J Thromb Haemost, 18 (5), 1094-1099. doi:10.1111/jth.14817
Tardif, J. C., Kouz, S., Waters, D. D., Bertrand, O. F., Diaz, R., Maggioni, A. P., . . . Roubille, F. (2019). Efficacy and Safety of Low-Dose Colchicine after Myocardial Infarction. N Engl J Med, 381 (26), 2497-2505. doi:10.1056/NEJMoa1912388
Thygesen, K., Alpert, J. S., Jaffe, A. S., Chaitman, B. R., Bax, J. J., Morrow, D. A., & White, H. D. (2018). Fourth Universal Definition of Myocardial Infarction (2018). J Am Coll Cardiol, 72 (18), 2231-2264. doi:10.1016/j.jacc.2018.08.1038
Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. (2021).Lancet, 397 (10285), 1637-1645. doi:10.1016/s0140-6736(21)00676-0
Tufan, A., Avanoğlu Güler, A., & Matucci-Cerinic, M. (2020). COVID-19, immune system response, hyperinflammation and repurposing antirheumatic drugs. Turk J Med Sci, 50 (Si-1), 620-632. doi:10.3906/sag-2004-168
Verity, R., Okell, L. C., Dorigatti, I., Winskill, P., Whittaker, C., Imai, N., . . . Ferguson, N. M. (2020). Estimates of the severity of coronavirus disease 2019: a model-based analysis. Lancet Infect Dis, 20 (6), 669-677. doi:10.1016/s1473-3099(20)30243-7
Vora, S. M., Lieberman, J., & Wu, H. (2021). Inflammasome activation at the crux of severe COVID-19. Nat Rev Immunol, 21 (11), 694-703. doi:10.1038/s41577-021-00588-x
Webb, B. J., Peltan, I. D., Jensen, P., Hoda, D., Hunter, B., Silver, A., . . . Brown, S. M. (2020). Clinical criteria for COVID-19-associated hyperinflammatory syndrome: a cohort study. Lancet Rheumatol, 2 (12), e754-e763. doi:10.1016/s2665-9913(20)30343-x
Table 1 : Baseline clinical and laboratory features and outcomes of the patients before and after Propensity-score (PS) Matching